A cohort study assessing a blood test for early cancer detection in Nanjing
A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population
This study is testing a new blood test to see if it can detect different types of cancer earlier in people aged 45-75 in Nanjing, China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15000 (estimated) |
| Ages | 45 Years to 75 Years |
| Sex | All |
| Sponsor | Nanjing Shihejiyin Technology, Inc. Industry-sponsored |
| Locations | 2 sites (Nanjing, Jiangsu and 1 other locations) |
| Trial ID | NCT06011694 on ClinicalTrials.gov |
What this trial studies
The Jinling Cohort is a prospective, multicenter observational study involving 15,000 individuals aged 45-75 in Nanjing, China. Participants will undergo blood collection for the MERCURY multi-omics liquid biopsy test, complete health questionnaires, and annual physical exams over three years, followed by two additional years of follow-up. The study aims to evaluate the test's sensitivity, specificity, and predictive values, as well as its ability to detect multiple cancer types earlier than conventional methods. Additionally, it will assess participants' attitudes towards the MCED blood test.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 45-75 residing in Nanjing who are willing to participate in the study procedures.
Not a fit: Patients with a history of cancer, current cancer diagnosis, or certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of multiple cancers, potentially improving patient outcomes and reducing late-stage diagnoses.
How similar studies have performed: While similar approaches have been explored, the specific application of the MERCURY test in this cohort is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent Exclusion Criteria: 1. Pregnant women; 2. Individuals who have history of cancer or current diagnosis of cancer; 3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant; 4. Individulas who have blood transfusion within 30 days prior to the blood draw; 5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw; 6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw; 7. Individuals who will not be able to comply with the protocol procedures judged by researchers
Where this trial is running
Nanjing, Jiangsu and 1 other locations
- Nanjing Jiangbei People's Hospital — Nanjing, Jiangsu, China (Recruiting)
- The Fourth Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Shao Yang, Ph.D — NanjingShihejiyin Technology Inc.
- Study coordinator: Shanshan Yang, Ph.D
- Email: admin@geneseeq.com
- Phone: 8613585145836
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.